[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600566":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":82,"collaborators":86,"id":94,"slug":11,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":11,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":11,"enrollmentInfo":102,"targetDuration":11,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Brivudine Group","EXPERIMENTAL",null,[13],"Drug: Brivudine",{"label":15,"type":16,"description":11,"interventionNames":17},"Famciclovir Group","ACTIVE_COMPARATOR",[18],"Drug: Famciclovir",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Brivudine","brivudine 125 mg per dose, once daily, 7 days",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Famciclovir","orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Jin-Zhu Guo, M.D.","CONTACT","008613521115717","guojinzhu_826@163.com",[36,51,61,71],{"facility":5,"status":37,"city":38,"state":11,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Beijing","100191","China",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":32,"phone":50,"phoneExt":11,"email":34},"Jinzhu Guo, M.D.","008615611963350",{"facility":52,"status":37,"city":38,"state":11,"zip":11,"country":40,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Beijing Hospital of Traditional Chinese Medicine, Capital Medical University",{"type":42,"coordinates":54},[44,45],{"lat":45,"lon":44},[57],{"name":58,"role":32,"phone":59,"phoneExt":11,"email":60},"Dongmei Zhou, M.D.","008613811201580","52176857@163.com",{"facility":62,"status":37,"city":38,"state":11,"zip":11,"country":40,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Peking University First Hospital",{"type":42,"coordinates":64},[44,45],{"lat":45,"lon":44},[67],{"name":68,"role":32,"phone":69,"phoneExt":11,"email":70},"Xiaowen Wang, M.D.","008615901254602","xiaowenpku@126.com",{"facility":72,"status":73,"city":38,"state":11,"zip":11,"country":40,"cosmosGeoPoint":74,"geoPoint":76,"contacts":77},"Xuanwu Hospital, Capital Medical University","NOT_YET_RECRUITING",{"type":42,"coordinates":75},[44,45],{"lat":45,"lon":44},[78],{"name":79,"role":32,"phone":80,"phoneExt":11,"email":81},"Haiping Zhang, M.D.","008613701205765","zhanghaiping@xwhosp.org",{"type":83,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Guo Jin-Zhu","Deputy Director of Dermatology",[87,88,90,92],{"name":62,"class":6},{"name":89,"class":6},"Air Force Military Medical University, China",{"name":91,"class":6},"Beijing Hospital of Traditional Chinese Medicine",{"name":93,"class":6},"Xuanwu Hospital, Beijing","100600566",false,"NCT07099157","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender;\n2. Signed Informed Consent Form;\n3. Female subjects must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:\n\n   * Barrier methods: Condom or barrier cap (diaphragm or cervical cap);\n   * Intrauterine device (IUD) or intrauterine system (IUS);\n   * Surgical sterilization (bilateral oophorectomy with\u002Fwithout hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;\n   * Other investigator-confirmed highly effective physical contraception.\n\nExclusion Criteria:\n\n1. Allergy to brivudine, famciclovir, or penciclovir;\n2. Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);\n3. Cancer patients currently undergoing chemotherapy;\n4. Pregnant or lactating women;\n5. Parkinson's disease;\n6. Any condition deemed inappropriate for study participation by the investigator.","ALL","18 Years",{"count":103,"type":104},140,"ESTIMATED","INTERVENTIONAL",[107],"PHASE4","This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3\u002FDay 7\u002FDay 14\u002FDay 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.",[110],"Herpes Zoster",[110,22,112,113],"pain","treatment","2025-12-28",{"date":116,"type":117},"2026-01-02","ACTUAL",{"date":119,"type":117},"2025-08-25",{"date":121,"type":104},"2027-12-31",{"name":5,"class":6},4]